Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction
Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, exploratory study. Patients with advanced esophageal or
gastro-esophageal junction squamous carcinoma who had progressed on first-line chemotherapy
combined with immune checkpoint inhibitors were treated with CDK4/6 inhibitor Palbociclib
combined with Afatinib. Dose titration was used to determine the final dose, and objective
antitumor efficacy was evaluated every 2 cycles (8 weeks +/- 7 days) according to RECIST 1.1
criteria, until tumor progression, intolerable toxicity, death, or withdrawal of informed
consent. The primary endpoint is the objective response rate (ORR).